{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:38:49Z","timestamp":1761824329989,"version":"build-2065373602"},"reference-count":73,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.hoc.2021.09.003","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T22:45:43Z","timestamp":1637189143000},"page":"133-146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Biology and Treatment of Meningiomas"],"prefix":"10.1016","volume":"36","author":[{"given":"J. Ricardo","family":"McFaline-Figueroa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Kaley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian F.","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenya Linda","family":"Bi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12 Suppl 2","key":"10.1016\/j.hoc.2021.09.003_bib1","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noaa200","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017","volume":"22","author":"Ostrom","year":"2020","journal-title":"Neuro Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2021.09.003_bib2","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/neuonc\/nov069","article-title":"Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States","volume":"17","author":"Kshettry","year":"2015","journal-title":"Neuro Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2021.09.003_bib3","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/ijc.21255","article-title":"Incidence of intracranial meningiomas in Denmark, Finland, Norway and Sweden, 1968-1997","volume":"117","author":"Klaeboe","year":"2005","journal-title":"Int J Cancer J Int du Cancer"},{"issue":"6123","key":"10.1016\/j.hoc.2021.09.003_bib4","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1126\/science.1233009","article-title":"Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO","volume":"339","author":"Clark","year":"2013","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.hoc.2021.09.003_bib5","first-page":"345","article-title":"SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas","volume":"19","author":"Boetto","year":"2017","journal-title":"Neuro Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2021.09.003_bib6","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/neuonc\/nox018","article-title":"Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1\/2 activation and reduced time to tumor recurrence","volume":"19","author":"Yesiloz","year":"2017","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2021.09.003_bib7","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/neuros\/nyaa038","article-title":"Is falcine meningioma a diffuse disease of the Falx? Case series and analysis of a \"grade zero\" resection","volume":"87","author":"Mooney","year":"2020","journal-title":"Neurosurgery"},{"year":"1998","series-title":"Operative atlas of meningiomas","author":"Al-Mefty","key":"10.1016\/j.hoc.2021.09.003_bib8"},{"key":"10.1016\/j.hoc.2021.09.003_bib9","series-title":"Al-Mefty's meningiomas","first-page":"432","author":"Al-Mefty","year":"2011"},{"key":"10.1016\/j.hoc.2021.09.003_bib10","first-page":"1","article-title":"Natural history of cavernous sinus meningiomas","volume":"1","author":"Amelot","year":"2018","journal-title":"J\u00a0Neurosurg"},{"issue":"3","key":"10.1016\/j.hoc.2021.09.003_bib11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/ng.2552","article-title":"Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas","volume":"45","author":"Smith","year":"2013","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.hoc.2021.09.003_bib12","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/nan.12397","article-title":"WHO 2016 classification: changes and advancements in the diagnosis of miscellaneous primary CNS tumours","volume":"44","author":"Sahm","year":"2018","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"3","key":"10.1016\/j.hoc.2021.09.003_bib13","first-page":"525","article-title":"Genomic landscape of intracranial meningiomas","volume":"125","author":"Bi","year":"2016","journal-title":"J\u00a0Neurosurg"},{"issue":"9","key":"10.1016\/j.hoc.2021.09.003_bib14","first-page":"2046","article-title":"Malignancy\" in meningiomas: a clinicopathologic study of 116 patients, with grading implications","volume":"85","author":"Perry","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2021.09.003_bib15","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.wneu.2016.06.055","article-title":"Brain invasion in meningiomas: incidence and correlations with clinical variables and prognosis","volume":"93","author":"Spille","year":"2016","journal-title":"World Neurosurg"},{"issue":"3","key":"10.1016\/j.hoc.2021.09.003_bib16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00401-016-1598-1","article-title":"Brain invasion in otherwise benign meningiomas does not predict tumor recurrence","volume":"132","author":"Baumgarten","year":"2016","journal-title":"Acta Neuropathol"},{"issue":"10","key":"10.1016\/j.hoc.2021.09.003_bib17","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1093\/neuonc\/nox071","article-title":"Brain invasion in meningiomas-clinical considerations and impact of neuropathological evaluation: a systematic review","volume":"19","author":"Brokinkel","year":"2017","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2021.09.003_bib18","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s11060-019-03312-x","article-title":"Microscopic brain invasion in meningiomas previously classified as WHO grade I is not associated with patient outcome","volume":"145","author":"Biczok","year":"2019","journal-title":"J\u00a0Neurooncol"},{"issue":"4","key":"10.1016\/j.hoc.2021.09.003_bib19","first-page":"535","article-title":"Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas","volume":"19","author":"Shankar","year":"2017","journal-title":"Neuro Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2021.09.003_bib20","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/jnci\/djy171","article-title":"Comprehensive study of the clinical phenotype of germline BAP1 variant-carrying families worldwide","volume":"110","author":"Walpole","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.hoc.2021.09.003_bib21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00401-020-02161-7","article-title":"Frequent inactivating mutations of the PBAF complex gene PBRM1 in meningioma with papillary features","volume":"140","author":"Williams","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1016\/j.hoc.2021.09.003_bib22","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s40478-020-01040-2","article-title":"Distinct genomic subclasses of high-grade\/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic","volume":"8","author":"Williams","year":"2020","journal-title":"Acta Neuropathol Commun"},{"issue":"8","key":"10.1016\/j.hoc.2021.09.003_bib23","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2021.09.003_bib24","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/bpa.12110","article-title":"High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression","volume":"24","author":"Goutagny","year":"2014","journal-title":"Brain Pathol"},{"issue":"6","key":"10.1016\/j.hoc.2021.09.003_bib25","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.cancergen.2015.03.005","article-title":"ARID1A and TERT promoter mutations in dedifferentiated meningioma","volume":"208","author":"Abedalthagafi","year":"2015","journal-title":"Cancer Genet"},{"issue":"5","key":"10.1016\/j.hoc.2021.09.003_bib26","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv377","article-title":"TERT promoter mutations and risk of recurrence in meningioma","volume":"108","author":"Sahm","year":"2016","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"65","key":"10.1016\/j.hoc.2021.09.003_bib27","doi-asserted-by":"crossref","first-page":"109228","DOI":"10.18632\/oncotarget.22650","article-title":"Intratumoral heterogeneity and TERT promoter mutations in progressive\/higher-grade meningiomas","volume":"8","author":"Juratli","year":"2017","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.hoc.2021.09.003_bib28","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/neuonc\/noy104","article-title":"TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma","volume":"20","author":"Spiegl-Kreinecker","year":"2018","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2021.09.003_bib29","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0002-9440(10)61737-3","article-title":"Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas","volume":"159","author":"Bostrom","year":"2001","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1016\/j.hoc.2021.09.003_bib30","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1023\/A:1013863630293","article-title":"Alterations of INK4a(p16-p14ARF)\/INK4b(p15) expression and telomerase activation in meningioma progression","volume":"55","author":"Simon","year":"2001","journal-title":"J\u00a0Neurooncol"},{"issue":"2","key":"10.1016\/j.hoc.2021.09.003_bib31","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1750-3639.2002.tb00433.x","article-title":"A\u00a0role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas","volume":"12","author":"Perry","year":"2002","journal-title":"Brain Pathol"},{"issue":"6","key":"10.1016\/j.hoc.2021.09.003_bib32","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/ijc.11013","article-title":"Immunohistochemical analysis of p16INK4a, p14ARF, p18INK4c, p21CIP1, p27KIP1 and p73 expression in 271 meningiomas correlation with tumor grade and clinical outcome","volume":"104","author":"Korshunov","year":"2003","journal-title":"Int J Cancer J Int du Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2021.09.003_bib33","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00401-020-02188-w","article-title":"CDKN2A\/B homozygous deletion is associated with early recurrence in meningiomas","volume":"140","author":"Sievers","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"5","key":"10.1016\/j.hoc.2021.09.003_bib34","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/neuonc\/not325","article-title":"Proposal for a new risk stratification classification for meningioma based on patient age, WHO tumor grade, size, localization, and karyotype","volume":"16","author":"Domingues","year":"2014","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2021.09.003_bib35","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S1470-2045(17)30155-9","article-title":"DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis","volume":"18","author":"Sahm","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2021.09.003_bib36","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/neuonc\/noz061","article-title":"DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management","volume":"21","author":"Nassiri","year":"2019","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.hoc.2021.09.003_bib37","article-title":"A\u00a0molecularly integrated grade for meningioma","author":"Driver","year":"2021","journal-title":"Neuro Oncol"},{"issue":"7874","key":"10.1016\/j.hoc.2021.09.003_bib38","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41586-021-03850-3","article-title":"A\u00a0clinically applicable integrative molecular classification of meningiomas","volume":"597","author":"Nassiri","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.hoc.2021.09.003_bib39","article-title":"Integrated phospho-proteogenomic and single-cell transcriptomic analysis of meningiomas establishes robust subtyping and reveals subtype-specific immune invasion","author":"Blume","year":"2021","journal-title":"bioRxiv"},{"issue":"6","key":"10.1016\/j.hoc.2021.09.003_bib40","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00401-018-1844-9","article-title":"Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence","volume":"135","author":"Katz","year":"2018","journal-title":"Acta Neuropathol"},{"issue":"7","key":"10.1016\/j.hoc.2021.09.003_bib41","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/jnen\/nlaa038","article-title":"Prognostic value of histopathological features and loss of H3K27me3 immunolabeling in anaplastic meningioma: a multicenter retrospective study","volume":"79","author":"Gauchotte","year":"2020","journal-title":"J\u00a0Neuropathol Exp Neurol"},{"key":"10.1016\/j.hoc.2021.09.003_bib42","article-title":"H3K27me3 loss indicates an increased risk of recurrence in the Tubingen meningioma cohort","author":"Behling","year":"2020","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2021.09.003_bib43","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/neuonc\/noaa226","article-title":"Associations of meningioma molecular subgroup and tumor recurrence","volume":"23","author":"Youngblood","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.hoc.2021.09.003_bib44","article-title":"An international multicenter matched cohort analysis of incidental meningioma progression during active surveillance or after stereotactic radiosurgery: the IMPASSE study","author":"Sheehan","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.hoc.2021.09.003_bib45","doi-asserted-by":"crossref","first-page":"e804","DOI":"10.1016\/j.wneu.2019.10.002","article-title":"Atypical histopathological features and the risk of treatment failure in nonmalignant meningiomas: a multi-institutional analysis","volume":"133","author":"Lamba","year":"2020","journal-title":"World Neurosurg"},{"issue":"2","key":"10.1016\/j.hoc.2021.09.003_bib46","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00701-013-1923-6","article-title":"Simpson grade: an opportunity to reassess the need for complete resection of meningiomas","volume":"156","author":"Heald","year":"2014","journal-title":"Acta Neurochir (Wien)"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2021.09.003_bib47","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/neuonc\/noy178","article-title":"Molecular and translational advances in meningiomas","volume":"21","author":"Suppiah","year":"2019","journal-title":"Neuro Oncol"},{"issue":"24","key":"10.1016\/j.hoc.2021.09.003_bib48","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.1002\/cncr.29639","article-title":"Extent of resection and overall survival for patients with atypical and malignant meningioma","volume":"121","author":"Aizer","year":"2015","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.hoc.2021.09.003_bib49","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/0090-3019(86)90259-4","article-title":"Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis","volume":"26","author":"Jaaskelainen","year":"1986","journal-title":"Surg Neurol"},{"issue":"2","key":"10.1016\/j.hoc.2021.09.003_bib50","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s10143-019-01117-0","article-title":"WHO grade I meningiomas: classification-tree for prognostic factors of survival","volume":"43","author":"Lemee","year":"2020","journal-title":"Neurosurg Rev"},{"issue":"3","key":"10.1016\/j.hoc.2021.09.003_bib51","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00701-016-3071-2","article-title":"Volumetric growth rates of meningioma and its correlation with histological diagnosis and clinical outcome: a systematic review","volume":"159","author":"Fountain","year":"2017","journal-title":"Acta Neurochir (Wien)"},{"issue":"1","key":"10.1016\/j.hoc.2021.09.003_bib52","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1136\/jnnp.20.1.22","article-title":"The recurrence of intracranial meningiomas after surgical treatment","volume":"20","author":"Simpson","year":"1957","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"7","key":"10.1016\/j.hoc.2021.09.003_bib53","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/cncr.11645","article-title":"Radiotherapy alone or after subtotal resection for benign skull base meningiomas","volume":"98","author":"Mendenhall","year":"2003","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.hoc.2021.09.003_bib54","doi-asserted-by":"crossref","first-page":"e383","DOI":"10.1016\/S1470-2045(16)30321-7","article-title":"EANO guidelines for the diagnosis and treatment of meningiomas","volume":"17","author":"Goldbrunner","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2021.09.003_bib56","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12094-020-02434-3","article-title":"Role of adjuvant radiotherapy in atypical (WHO grade II) and anaplastic (WHO grade III) meningiomas: a systematic review","volume":"23","author":"Delgado-Lopez","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.hoc.2021.09.003_bib57","doi-asserted-by":"crossref","first-page":"568079","DOI":"10.3389\/fonc.2020.568079","article-title":"Prognostic model that predicts benefits of adjuvant radiotherapy in patients with high grade meningioma","volume":"10","author":"Wang","year":"2020","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2021.09.003_bib58","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/neuonc\/not330","article-title":"Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review","volume":"16","author":"Kaley","year":"2014","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2021.09.003_bib59","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/neuonc\/nou148","article-title":"Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma","volume":"17","author":"Kaley","year":"2015","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2021.09.003_bib60","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11060-012-0886-4","article-title":"Atypical and anaplastic meningiomas treated with bevacizumab","volume":"109","author":"Nayak","year":"2012","journal-title":"J\u00a0Neurooncol"},{"issue":"1","key":"10.1016\/j.hoc.2021.09.003_bib61","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11060-012-0861-0","article-title":"Bevacizumab therapy for adults with recurrent\/progressive meningioma: a retrospective series","volume":"109","author":"Lou","year":"2012","journal-title":"J\u00a0Neurooncol"},{"issue":"2","key":"10.1016\/j.hoc.2021.09.003_bib62","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11060-016-2172-3","article-title":"A\u00a0phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma","volume":"129","author":"Shih","year":"2016","journal-title":"J\u00a0Neurooncol"},{"issue":"1\u20132","key":"10.1016\/j.hoc.2021.09.003_bib63","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1023\/B:NEON.0000013498.19981.55","article-title":"Expression of somatostatin receptor mRNA in human meningiomas and their implication in in\u00a0vitro antiproliferative activity","volume":"66","author":"Arena","year":"2004","journal-title":"J\u00a0Neurooncol"},{"issue":"5","key":"10.1016\/j.hoc.2021.09.003_bib64","first-page":"1865","article-title":"Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A","volume":"6","author":"Schulz","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.hoc.2021.09.003_bib65","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1212\/01.wnl.0000271382.62776.b7","article-title":"Recurrent meningioma: salvage therapy with long-acting somatostatin analogue","volume":"69","author":"Chamberlain","year":"2007","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.hoc.2021.09.003_bib66","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1212\/WNL.0000000000001153","article-title":"Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma","volume":"84","author":"Norden","year":"2015","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.hoc.2021.09.003_bib67","first-page":"1538","article-title":"Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE\/-TOC uptake","volume":"18","author":"Seystahl","year":"2016","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2021.09.003_bib68","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/ng.2526","article-title":"Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations","volume":"45","author":"Brastianos","year":"2013","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.hoc.2021.09.003_bib69","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/neuonc\/nov316","article-title":"Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma","volume":"18","author":"Abedalthagafi","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.hoc.2021.09.003_bib70","article-title":"Genomic landscape of high-grade meningiomas","volume":"2","author":"Bi","year":"2017","journal-title":"NPJ Genomic Med"},{"key":"10.1016\/j.hoc.2021.09.003_bib71","doi-asserted-by":"crossref","unstructured":"Bi WL, Nayak L, Meredith DM, et al. Activity of PD-1 blockade with Nivolumab among patients with recurrent atypical\/anaplastic meningioma: phase II trial results. Neuro Oncol 2021. https:\/\/doi.org\/10.1093\/neuonc\/noab118.","DOI":"10.1093\/neuonc\/noab118"},{"issue":"1","key":"10.1016\/j.hoc.2021.09.003_bib72","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/neuonc\/noy137","article-title":"Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group","volume":"21","author":"Huang","year":"2019","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2021.09.003_bib73","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/1078-0432.CCR-19-2109","article-title":"Everolimus and octreotide for patients with recurrent meningioma: results from the phase II CEVOREM Trial","volume":"26","author":"Graillon","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.hoc.2021.09.003_bib74","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1093\/neuonc\/noab019","article-title":"Role of 3D volume growth rate for drug activity evaluation in meningioma clinical trials: the example of the CEVOREM study","volume":"23","author":"Graillon","year":"2021","journal-title":"Neuro Oncol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858821001180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858821001180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:18:45Z","timestamp":1760185125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858821001180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0889858821001180"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2021.09.003","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biology and Treatment of Meningiomas","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2021.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}